Atrium Therapeutics Inc

NAS:RNAHealthcareCBOEFTSE:MRUTNASDAQ:NQUSSG

$7.98+4.86%At closeAt close · Wed 21 Oct · ≈ AED 29.31 · Market cap $177.76M · Next earnings Thu 12 Nov

Ratio	FY2023	FY2024	FY2025	Current · undated	YoY
Gross margin	98.6%	98.4%	100.0%	—	—
Operating margin	−65.4%	−121.3%	−412.6%	−412.6%	+0.0 pts
Net margin	−65.4%	−230.5%	−411.9%	−265.9%	+146.0 pts
EBITDA margin	−64.0%	−119.7%	−410.9%	—	—
Return on equity	9.0%	41.1%	−37.0%	−23.9%	+13.1 pts
Return on assets	−51.0%	−287.7%	−27.5%	−17.8%	+9.8 pts
Return on capital employed	30.0%	73.1%	−32.5%	—	—
Debt / equity	−0.1×	−0.1×	0.0×	0.0×	+0.0%
Debt / assets	78.7%	77.9%	1.3%	—	—
Interest coverage	0.0×	0.0×	0.0×	—	—
Current ratio	0.0×	0.0×	6.5×	6.5×	+0.0%
Quick ratio	0.0×	0.0×	6.5×	—	—
Cash ratio	0.0×	0.0×	6.5×	6.5×	+0.0%
Asset turnover	0.8×	1.2×	0.1×	—	—
Receivables turnover	13.0×	—	—	—	—
Dividend payout	0.0%	0.0%	0.0%	—	—

Margins, returns, leverage and liquidityUpdated 31 Dec 2025 ·

ⓘ

Current snapshot ratios have no reporting date and are shown separately from fiscal periods.